Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume

Pharming Group (NASDAQ:PHAR) shares saw unusually-high trading volume on Thursday . Approximately 2,510 shares traded hands during mid-day trading, a decline of 2% from the previous session’s volume of 2,557 shares.The stock last traded at $9.37 and had previously closed at $10.45.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, March 14th.

Pharming Group Price Performance

The stock has a 50-day moving average of $10.75 and a two-hundred day moving average of $11.37. The firm has a market cap of $646.27 million, a price-to-earnings ratio of -68.42 and a beta of 0.20. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.62.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. On average, analysts anticipate that Pharming Group will post -0.02 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new position in Pharming Group (NASDAQ:PHAR) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 11,715 shares of the company’s stock, valued at approximately $134,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.